Cardiac Iron Determines Cardiac T2*, T2, and T1 in the Gerbil Model of Iron Cardiomyopathy
暂无分享,去创建一个
Thomas D. Coates | Marvin D. Nelson | Rex Moats | Michelle Aguilar | John C. Wood | R. Moats | T. Coates | M. Nelson | J. Wood | Maya Otto-Duessel | Hanspeter Nick | Harvey Pollack | H. Nick | M. Otto‐Duessel | H. Pollack | Michelle Aguilar
[1] C. McLaren,et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. , 1994, The New England journal of medicine.
[2] S. Huffel,et al. Anticipation of epileptic seizures from standard EEG recordings , 2003, The Lancet.
[3] R. Brooks,et al. Relaxometry and magnetometry of the MR contrast agent MION‐46L , 1999, Magnetic resonance in medicine.
[4] H. Eiskjaer,et al. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. , 2003, Blood.
[5] T. S. St. Pierre,et al. Organ-specific crystalline structures of ferritin cores inβ-thalassemia/hemoglobin E , 2005, Biology of Metals.
[6] Marvin D Nelson,et al. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. , 2004, Blood.
[7] J. H. MacMillan,et al. Survival in medically treated patients with homozygous beta-thalassemia. , 1994, The New England journal of medicine.
[8] K. Ehlers,et al. Beta thalassemia and heart disease: three decades of gradual progress. , 1985, Transactions of the American Clinical and Climatological Association.
[9] D. Weatherall,et al. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility , 2003, The Lancet.
[10] T. S. St. Pierre,et al. Proton transverse relaxation rate (R2) images of iron‐loaded liver tissuepping local tissue iron concentrations with MRI , 2003 .
[11] F. Blei,et al. Chelation therapy and cardiac status in older patients with thalassemia major. , 1990, The American journal of pediatric hematology/oncology.
[12] A. Tanimoto,et al. Relaxation effects of clustered particles , 2001, Journal of magnetic resonance imaging : JMRI.
[13] T. Ur,et al. Differential induction of polyamine oxidase activity in liver and heart of iron-overloaded rats. , 1997 .
[14] P. Greenberg,et al. Major hematologic diseases in the developing world- new aspects of diagnosis and management of thalassemia, malarial anemia, and acute leukemia. , 2001, Hematology. American Society of Hematology. Education Program.
[15] D. Fitchett,et al. Cardiac involvement in secondary haemochromatosis: a catheter biopsy study and analysis of myocardium. , 1980, Cardiovascular research.
[16] S. Shaughnessy,et al. Do No Harm: Health Systems’ Duty to Promote Clinician Well-Being , 2022, American Journal of Hospital Medicine.
[17] T. S. St. Pierre,et al. Single spin‐echo proton transverse relaxometry of iron‐loaded liver , 2004, NMR in biomedicine.
[18] K. Ehlers,et al. LONGITUDINAL STUDY OF CARDIAC FUNCTION IN THALASSEMIA MAJOR * , 1980, Annals of the New York Academy of Sciences.
[19] T. S. St. Pierre. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. , 2003, Lancet.
[20] Mark A Westwood,et al. Interscanner reproducibility of cardiovascular magnetic resonance T2* measurements of tissue iron in thalassemia , 2003, Journal of magnetic resonance imaging : JMRI.
[21] B. Gersh,et al. Cardiac iron deposition in idiopathic hemochromatosis: histologic and analytic assessment of 14 hearts from autopsy. , 1987, Journal of the American College of Cardiology.
[22] Gary M Brittenham,et al. Optical mapping reveals conduction slowing and impulse block in iron-overload cardiomyopathy. , 2003, The Journal of laboratory and clinical medicine.
[23] J. Marx,et al. The Amount of Ferritin and Hemosiderin in the Livers of Patients with Iron‐Loading Diseases , 2007, Hepatology.
[24] Y. Kuryshev,et al. Decreased sodium and increased transient outward potassium currents in iron-loaded cardiac myocytes. Implications for the arrhythmogenesis of human siderotic heart disease. , 1999, Circulation.
[25] M. N. Levy,et al. Bimodal cardiac dysfunction in an animal model of iron overload. , 2002, The Journal of laboratory and clinical medicine.
[26] R. Engelhardt,et al. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility , 2003, The Lancet.
[27] D. Tsiapras,et al. Heart failure in beta thalassemia: a 5-year follow-up study. , 2001, The American journal of medicine.
[28] M. Bock,et al. Changes in myocardial oxygenation and perfusion under pharmacological stress with dipyridamole: Assessment using T*2 and T1 measurements , 1999, Magnetic resonance in medicine.
[29] M. F. Khan,et al. Differential induction of polyamine oxidase activity in liver and heart of iron-overloaded rats. , 1997, Journal of toxicology and environmental health.
[30] N. Olivieri,et al. Quantification of cardiac and tissue iron by nuclear magnetic resonance relaxometry in a novel murine thalassemia-cardiac iron overload model. , 1996, The Canadian journal of cardiology.
[31] B. Rosen,et al. Microscopic susceptibility variation and transverse relaxation: Theory and experiment , 1994, Magnetic resonance in medicine.
[32] D. Pennell,et al. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia , 2002, The Lancet.
[33] W. Edwards,et al. Endomyocardial biopsy in hemochromatosis: clinicopathologic correlates in six cases. , 1989, Journal of the American College of Cardiology.
[34] W. Roberts,et al. Iron in the heart. Etiology and clinical significance. , 1971, The American journal of medicine.
[35] D N Firmin,et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. , 2001, European heart journal.
[36] E. T. Adams,et al. Morphologic Investigations of the Guinea Pig Model of Iron Overload , 1993, Toxicologic pathology.
[37] M. N. Levy,et al. Deferoxamine promotes survival and prevents electrocardiographic abnormalities in the gerbil model of iron-overload cardiomyopathy. , 2003, The Journal of laboratory and clinical medicine.
[38] M. Jessup,et al. Diagnosis and Management of Iron‐induced Heart Disease in Cooley's Anemia , 1998, Annals of the New York Academy of Sciences.
[39] T. S. St. Pierre,et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. , 2005, Blood.
[40] D. Weatherall. Thalassemia in the Next Millennium: Keynote Address a , 1998, Annals of the New York Academy of Sciences.
[41] J. H. MacMillan,et al. Survival in Medically Treated Patients with Homozygous β-Thalassemia , 1994 .
[42] Huaqing Zhao,et al. 1/T2 and magnetic susceptibility measurements in a gerbil cardiac iron overload model. , 2005, Radiology.
[43] A. Hoffbrand,et al. High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. , 1990, Acta haematologica.
[44] D. Pennell,et al. A single breath‐hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload , 2003, Journal of magnetic resonance imaging : JMRI.
[45] G. Brittenham,et al. Iron-chelating therapy and the treatment of thalassemia. , 1997, Blood.